摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

p-methylphenyl 2-deoxy-2-azido-1-thio-β-D-galactopyranoside | 125760-22-7

中文名称
——
中文别名
——
英文名称
p-methylphenyl 2-deoxy-2-azido-1-thio-β-D-galactopyranoside
英文别名
4-methylphenyl 2-azido-2-deoxy-1-thio-β-D-galactopyranoside;p-tolyl 2-azido-2-deoxy-1-thio-β-D-galactopyranoside;(2R,3R,4R,5R,6S)-5-azido-2-(hydroxymethyl)-6-(4-methylphenyl)sulfanyloxane-3,4-diol
p-methylphenyl 2-deoxy-2-azido-1-thio-β-D-galactopyranoside化学式
CAS
125760-22-7
化学式
C13H17N3O4S
mdl
——
分子量
311.362
InChiKey
LGUQMWRHZKDLEU-LBELIVKGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    110
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    源自粘蛋白和 T 细胞刺激肽的唾液酸化糖肽的化学酶法合成
    摘要:
    Tn、T、sialyl-Tn 和 2,3-sialyl-T 抗原是在上皮癌(例如影响乳腺癌、卵巢癌、胃癌和结肠癌)的粘蛋白上表达的肿瘤相关碳水化合物抗原。携带这些抗原的糖肽对开发癌症疫苗很有意义,并且有报道称其合成的短化学酶促策略。制备与 Tn (GalNAc alpha-Ser/Thr) 和 T [Gal beta(1-->3)GalNAc alpha-Ser/Thr] 抗原相对应的结构单元,这些抗原相对容易通过化学合成获得,然后使用在固相上合成糖肽。引入唾液酸得到唾液酸-Tn [Neu5Ac alpha(2-->6)GalNAc alpha-Ser/Thr] 和 2,3-唾液酸-T [Neu5Ac alpha(2-->3)Gal beta(1- -> 3)GalNAc α-Ser/Thr] 抗原在构建模块水平上进行化学处理时是困难的。因此,在从固相裂解 Tn 和 T 糖肽后,在溶液中用
    DOI:
    10.1021/ja015570t
  • 作为产物:
    描述:
    参考文献:
    名称:
    基于硫糖基供体的预激活的肿瘤相关碳水化合物抗原Globo-H的多组分一锅法合成
    摘要:
    快速组装肿瘤相关碳水化合物抗原Globo-H六糖2的两种有效途径通过基于预激活的迭代一锅策略进行了报道。第一种方法涉及四个糖基结构单元的顺序偶联,从而在一锅合成中以47%的总收率产生所需的六糖。尽管在Gb3三糖中构建具有挑战性的Gal-α-(1-4)-Gal键的模型研究几乎仅产生了所需的α键,但组装六糖的相似方法导致形成了大量的β异头物。作为替代方案,第二种合成在一个锅中利用了三种成分,并预先形成了Gal-α-(1-4)-Gal键,从而以与四成分方法相似的总收率生产了所需的六糖。两种方法均表明,通过基于预激活的方法,与自动固相合成策略相比,具有更高的糖组装效率,可以在一个罐中构建在同一分子中包含α和β键的寡糖。此外,由于糖基化可以独立于供体的端基异构体反应性进行,因此不需要通过针对化学选择性糖基化的广泛保护基调节来区分构件的端基异构体反应性。这赋予了构件设计极大的灵活性,使供体与受体匹配,
    DOI:
    10.1021/jo070585g
点击查看最新优质反应信息

文献信息

  • Tuning Reactivity of Glycosyl Imidinium Intermediate for 2-Azido-2-deoxyglycosyl Donors in α-Glycosidic Bond Formation
    作者:Arun B. Ingle、Chin-Sheng Chao、Wei-Cheng Hung、Kwok-Kong Tony Mong
    DOI:10.1021/ol402519c
    日期:2013.10.18
    The chemical properties of nucleophile additives were investigated in a modulated glycosylation context. N-Formylmorpholine (NFM) was found to be an effective modulator for glycosylation with less reactive 2-azido-2-deoxythioglucosyl and thiogalactosyl donors.
    亲核添加剂的化学性质在调制的糖基化环境下进行了研究。发现N-甲酰基吗啉(NFM)是具有较低反应性的2-叠氮基-2-脱氧硫代葡糖基和硫代半乳糖基供体的糖基化的有效调节剂。
  • Synthesis of Tn and sialyl Tn building blocks for solid phase glycopeptide synthesis
    作者:Mikael Elofsson、Jan Kihlberg
    DOI:10.1016/0040-4039(95)01515-9
    日期:1995.10
    blocks for direct use in Fmoc solid phase glycopeptide synthesis have been prepared in 3 and 5 steps, respectively, from p-cresyl 2-azido-2-deoxy-3,6-di-O-tert-butyldimethylsilyl-1-thio-β-D-galactopyranoside (3). The silyl protective groups used for the GalNAc moiety of the Tn building block may be removed simultaneously with glycopeptide cleavage from the solid phase under acidic conditions.
    TN(GalNAcα1→ Ò -Thr)和唾液酸Tn(NeuAcα2→6GalNAcα1→ ö -Thr)在3层5的步骤,分别制备了用于在Fmoc固相合成的糖肽直接使用积木,从p -cresyl 2-叠氮基2-脱氧-3,6-二-O-叔丁基二甲基甲硅烷基-1-硫代-β-D-吡喃半乳糖苷(3)。可以在酸性条件下与糖肽从固相上裂解同时除去用于Tn结构单元的GalNAc部分的甲硅烷基保护基。
  • [EN] SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE<br/>[FR] OLIGOSACCHARIDES DE SYNTHÈSE POUR VACCIN CONTRE P. AERUGINOSA
    申请人:SYNGLYCO PHARMACEUTICALS INC
    公开号:WO2015002954A1
    公开(公告)日:2015-01-08
    The present invention provides synthetic Pseudomonas aeruginosa lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various P. aeruginosa serotype-specific oligosaccharide antigens or various core P. aeruginosa oligosaccharide structures or motifs. The invention further provides P. aeruginosa LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by P. aeruginosa.
    本发明提供了合成的假单胞菌脂寡糖(LOS)基寡糖和含有不同假单胞菌血清型特异性寡糖抗原或不同核心假单胞菌寡糖结构或基序的共轭物。该发明还提供了基于假单胞菌LOS的免疫原和免疫保护组合物,以及由此衍生的抗体,用于诊断、治疗和预防由假单胞菌引起的感染。
  • Programmable One-Pot Oligosaccharide Synthesis
    作者:Zhiyuan Zhang、Ian R. Ollmann、Xin-Shan Ye、Ralf Wischnat、Timor Baasov、Chi-Huey Wong
    DOI:10.1021/ja982232s
    日期:1999.2.1
    In an effort to develop a broadly applicable approach to the facile one-pot synthesis of oligosaccharides, the reactivity of a number of p-methylphenyl thioglycoside (STol) donors which are either fully protected or have one hydroxyl group exposed has been quantitatively determined by HPLC. We have characterized and quantified the influence on reactivity of the structural effects of different monosaccharide cores and different protecting groups on each glycoside donor. In addition, we have established a correlation between glycosyl donor reactivity and the chemical shift of the anomeric proton by H-1 NMR. Using the reactivity data, we have created a database of thioglycosides as glycosyl donors and demonstrated its utility in the easy and rapid one-pot assembly of various linear and branched oligosaccharide structures. In addition, we have developed the first computer program, OptiMer, for use as a database search tool and guide for the selection of building blocks for the one-pot assembly of a desired oligosaccharide or a library of individual oligosaccharides.
  • Synthesis of some amino and carboxy analogs of galabiose; evaluation as inhibitors of the pilus protein PapGJ96 from Escherichia coli
    作者:Henrik C. Hansen、Göran Magnusson
    DOI:10.1016/s0008-6215(98)00020-2
    日期:1998.2
    The 2'-amino-2'-deoxy, 6-amino-6-deoxy, and 6-carboxy analogs of the reference inhibitor 2-(trimethylsilyl)ethyl (alpha-D-galactopyranosyl)-(1-->4)-beta-D-galactopyranoside were synthesized and evaluated as inhibitors of the binding of the Escherichia coli-derived pilus protein PapG(J96), using an ELISA assay. The inhibitory efficiencies (K-rel; relative to the reference inhibitor) were: 157, 13, and < 8, respectively. The results support the previously proposed combining site model, where the protein carries a negatively charged amino acid residue near HO-2' and HO-6 of the galabioside. (C) 1998 Elsevier Science Ltd. All rights reserved.
查看更多